Next Article in Journal
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
Next Article in Special Issue
MicroRNA Regulation of Human Breast Cancer Stem Cells
Previous Article in Journal
Pork as a Source of Omega-3 (n-3) Fatty Acids
Previous Article in Special Issue
microRNA-34a as a Therapeutic Agent against Human Cancer
Article Menu

Export Article

Open AccessArticle

Detection of Exosomal miRNAs in the Plasma of Melanoma Patients

Department of Pathology and Laboratory Medicine, Center for Cancer Research, University of Tennessee Health Science Center, 19 South Manassas Street, Memphis, TN 38163, USA
Department of Oncology, University of Utah, Salt Lake City, UT 84112, USA
Department of Dermatology, Oregon Health & Science University, Portland, OR 97239, USA
Department of Medicine, Weill Cornell College of Medicine, New York, NY 10065, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Takahiro Ochiya and Ryou-u Takahashi
J. Clin. Med. 2015, 4(12), 2012-2027;
Received: 3 August 2015 / Revised: 1 December 2015 / Accepted: 4 December 2015 / Published: 17 December 2015
(This article belongs to the Special Issue MicroRNAs: Novel Biomarkers and Therapeutic Targets for Human Cancers)
PDF [1635 KB, uploaded 17 December 2015]


MicroRNAs (miRNAs) are a class of 22–25 nucleotide RNAs that control gene expression at the post-transcriptional level. MiRNAs have potential as cancer biomarkers. Melanoma is a highly aggressive form of skin cancer accounting for almost 4% of cancers among men and women, and ~80% of skin cancer-related deaths in the US. In the present study we analyzed plasma-derived exosomal miRNAs from clinically affected and unaffected familial melanoma patients (CDKN2A/p16 gene carriers) and compared them with affected (nonfamilial melanoma) and unaffected control subjects in order to identify novel risk biomarkers for melanoma. Intact miRNAs can be isolated from the circulation because of their presence in exosomes. A number of differentially regulated miRNAs identified by NanoString human V2 miRNA array were validated by quantitative PCR. Significantly, miR-17, miR-19a, miR-21, miR-126, and miR-149 were expressed at higher levels in patients with metastatic sporadic melanoma as compared with familial melanoma patients or unaffected control subjects. Surprisingly, no substantial differences in miRNA expression were detected between familial melanoma patients (all inclusive) and unaffected control subjects. The miRNAs differentially expressed in the different patient cohorts, especially in patients with metastatic melanoma, may play important roles in tumor progression and metastasis, and may be used as predictive biomarkers to monitor remission as well as relapse following therapeutic intervention. View Full-Text
Keywords: miRNAs; melanoma; exosomes; metastasis miRNAs; melanoma; exosomes; metastasis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Pfeffer, S.R.; Grossmann, K.F.; Cassidy, P.B.; Yang, C.H.; Fan, M.; Kopelovich, L.; Leachman, S.A.; Pfeffer, L.M. Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J. Clin. Med. 2015, 4, 2012-2027.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top